Table 3 Impact of cytogenetics on time and site of relapse, and overall survival post relapse among non-infant B-ALL patients.

From: Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study

Cytogeneticsa

No. of patients

No. of relapses (%)

5-yr from diagnosis EFS ± SE

Median time-to-relapse (months)

iBM relapse N (%)

Any BM relapse N (%)

iCNS relapse N (%)

Any CNS relapse N (%)

5-yr post relapse OS ± SE

Trisomy 4 + 10

2677

178 (6.6%)

92.6 ± 0.5%

43.3

108 (60.7%)

134 (75.3%)

31 (17.4%)

52 (29.2%)

70.2 ± 3.6%

ETV6::RUNX1

2555

213 (8.3%)

91.7 ± 0.6%

43.0

111 (52.1%)

151 (70.9%)

48 (22.5%)

77 (36.2%)

74.4 ± 3.1%

KMT2A-R

195

39 (20.0%)

70.2 ± 3.4%

18.0

23 (59.0%)

26 (66.7%)

6 (15.4%)

7 (17.9%)

31.9 ± 7.7%

TCF3::PBX1

414

57 (13.8%)

83.1 ± 1.9%

15.8

28 (49.1%)

31 (54.4%)

22 (38.6%)

25 (43.9%)

36.8 ± 6.6%

iAMP21

163

50 (30.7%)

68.5 ± 3.7%

43.6

31 (62.0%)

41 (82.0%)

8 (16.0%)

18 (36.0%)

48.2 ± 7.7%

BCR::ABL1

258

65 (25.2%)

52.4 ± 3.7%

35.3

52 (80.0%)

55 (84.6%)

8 (12.3%)

10 (15.4%)

47.2 ± 6.6%

Hypodiploid

178

36 (20.2%)

56.6 ± 4.1%

12.5

33 (91.7%)

34 (94.4%)

1 (2.8%)

2 (5.6%)

14.2 ± 6.1%

B-ALL, other

3654

669 (18.3%)

77.3 ± 0.7%

32.5

377 (56.4%)

472 (70.6%)

161 (24.1%)

246 (36.8%)

48.2 ± 2.0%

  1. ALL Acute Lymphoblastic Leukemia, BM Bone Marrow, CNS Central Nervous System, EFS Event-free Survival, i Isolated, OS Overall Survival, SE Standard Error.
  2. aAmong patients included in the table, 15 patients had two cytogenetic features. For these patients, the higher risk cytogenetic feature was used to group them in this table.
Back to article page